Zastaprazan for erosive reflux disease
Part of Digestive system clinical trials.
This study looks at how well JAQBO (zastaprazan) works and how safe it is for people with erosive reflux disease. It is an observational study, so you keep taking your medicine as prescribed and researchers simply collect information about your experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older
- You have been diagnosed with erosive reflux disease (acid reflux that damages the esophagus lining)
- You agree to take part and sign a consent form
- You are not allergic to zostaprazan (JAQBO) or any of its ingredients
- You are not pregnant, planning pregnancy, or breastfeeding
- You are not taking atazanavir, nelfinavir, or rilpivirine (HIV medications)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches patients with acute or chronic gastritis who are already being prescribed the stomach medicine Fexuclu (fexuprazan). It collects information to see how well the medicine works and if it causes any side effects in everyday use.
This trial tests if a new stomach acid medicine (Zastaprazan) affects how well clopidogrel works in heart patients who have had a stent placed. It aims to help people who need both clopidogrel and a stomach acid drug after a procedure.
This trial tests a new medicine called anaprazole for people with moderate to severe reflux esophagitis (chronic heartburn and damage to the food pipe). It compares anaprazole to a standard treatment to see which works better and is safer.
This trial tests a treatment for nighttime heartburn caused by GERD, a condition where stomach acid damages the esophagus. It is for adults who have had nighttime heartburn for more than 3 months and have been diagnosed with erosive GERD.
This trial tests whether fexuprazan can prevent upper gastrointestinal bleeding in people at high risk who need two antiplatelet drugs for at least 6 months after a heart stent. If you are on dual antiplatelet therapy after a stent and have risk factors like older age, low weight, or history of ulcers, this study may help protect your stomach.
This study looks at how well and how safely the drug tegoprazan works for people with gastroesophageal reflux disease (GERD). It may help if you have symptoms like heartburn or acid reflux.
Hear when a new Erosive Gastroesophageal Reflux Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.